Haemonetics Corporation
HAE
Rang în acțiuni
#3264
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Preț acțiune
$120.30
Capitalizare de piață
$5.47B
Schimbare (1 zi)
1.52%
Schimbare (1 an)
137.23%
Țară
US
Tranzacționează Haemonetics Corporation (HAE)
Categorie
Healthcare
Raport P/E pentru Haemonetics Corporation (HAE)
Raport P/E la data de October 2026 TTM: 58.79
Conform celor mai recente rapoarte financiare și prețului acțiunilor Haemonetics Corporation, raportul P/E actual (TTM) este 58.79. La sfârșitul anului 2024, compania avea un P/E de 36.57.
Istoricul raportului P/E pentru Haemonetics Corporation din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 58.79 | 209.92% |
| 2025 | 18.97 | -48.14% |
| 2024 | 36.57 | 0.43% |
| 2023 | 36.41 | -51.54% |
| 2022 | 75.14 | 5.15% |
| 2021 | 71.46 | 6.87% |
| 2020 | 66.87 | -18.39% |
| 2019 | 81.94 | -3.25% |
| 2018 | 84.69 | -206.46% |
| 2017 | -79.55 | 146.27% |
| 2016 | -32.30 | -123.96% |
| 2015 | 134.83 | 185.97% |
| 2014 | 47.15 | -14.48% |
| 2013 | 55.13 | 108.66% |
| 2012 | 26.42 | 26.60% |
| 2011 | 20.87 | -15.24% |
| 2010 | 24.62 | 5.04% |
| 2009 | 23.44 | -19.61% |
| 2008 | 29.16 | 14.54% |
| 2007 | 25.46 | 30.83% |
| 2006 | 19.46 | -27.03% |
| 2005 | 26.67 | 2.01% |
| 2004 | 26.14 | 34.39% |
| 2003 | 19.45 | -29.80% |
| 2002 | 27.71 | -76.06% |
| 2001 | 115.73 | 274.57% |
| 2000 | 30.90 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 33.11 | -43.68% |
US
|
|
| 21.39 | -63.62% |
IE
|
|
| 28.94 | -50.77% |
US
|
|
| 17.34 | -70.51% |
US
|
|
| - | - |
DE
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.